ES2194989T3 - Composicion adminstrada por via oral, que comprende una toxina de zonula occludens y un agente que tiene una actividad biologica, y su utilizacion. - Google Patents

Composicion adminstrada por via oral, que comprende una toxina de zonula occludens y un agente que tiene una actividad biologica, y su utilizacion.

Info

Publication number
ES2194989T3
ES2194989T3 ES96914626T ES96914626T ES2194989T3 ES 2194989 T3 ES2194989 T3 ES 2194989T3 ES 96914626 T ES96914626 T ES 96914626T ES 96914626 T ES96914626 T ES 96914626T ES 2194989 T3 ES2194989 T3 ES 2194989T3
Authority
ES
Spain
Prior art keywords
toxin
zonula
composition
oxludens
adminstrated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96914626T
Other languages
English (en)
Inventor
Alessio Fasano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland at Baltimore
Original Assignee
University of Maryland at Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/443,864 external-priority patent/US5827534A/en
Application filed by University of Maryland at Baltimore filed Critical University of Maryland at Baltimore
Application granted granted Critical
Publication of ES2194989T3 publication Critical patent/ES2194989T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UNA COMPOSICION DE DOSIFICACION ORAL PARA LA ADMINISTRACION INTESTINAL QUE COMPRENDE: (A) UN INGREDIENTE BIOLOGICAMENTE ACTIVO; Y (B) UNA TOXINA DE ZONULA OCCLUDENS, ASI COMO UN METODO PARA SU USO.
ES96914626T 1995-05-24 1996-05-16 Composicion adminstrada por via oral, que comprende una toxina de zonula occludens y un agente que tiene una actividad biologica, y su utilizacion. Expired - Lifetime ES2194989T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/443,864 US5827534A (en) 1995-05-24 1995-05-24 Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery
US08/598,852 US5665389A (en) 1995-05-24 1996-02-09 Oral dosage composition for intestinal delivery and method of treating diabetes

Publications (1)

Publication Number Publication Date
ES2194989T3 true ES2194989T3 (es) 2003-12-01

Family

ID=27033689

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96914626T Expired - Lifetime ES2194989T3 (es) 1995-05-24 1996-05-16 Composicion adminstrada por via oral, que comprende una toxina de zonula occludens y un agente que tiene una actividad biologica, y su utilizacion.

Country Status (9)

Country Link
US (1) US5665389A (es)
EP (1) EP0828481B1 (es)
JP (2) JP3846901B2 (es)
AT (1) ATE235893T1 (es)
AU (1) AU702385B2 (es)
CA (1) CA2222018A1 (es)
DE (1) DE69627147T2 (es)
ES (1) ES2194989T3 (es)
WO (1) WO1996037196A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908825A (en) * 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
US5912323A (en) * 1997-02-20 1999-06-15 University Of Maryland, Baltimore Zonula occludens toxin receptors
US5864014A (en) * 1997-02-20 1999-01-26 University Of Maryland At Baltimore Zonula occludens toxin receptor
US5945510A (en) * 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions
WO1999018792A1 (en) * 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
US6458925B1 (en) 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
US20030118547A1 (en) * 2000-01-27 2003-06-26 Vandenberg Grant William Composition for intestinal delivery
US7026294B2 (en) 2000-05-19 2006-04-11 University Of Maryland Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
CN100509842C (zh) 2003-01-10 2009-07-08 国家工业学院高级研究中心 轮状病毒蛋白、衍生的蛋白和肽在调节组织通透性中的应用
AU2004220544B2 (en) * 2003-03-06 2010-06-17 Emisphere Technologies, Inc. Oral insulin therapies and protocol
US7286223B2 (en) * 2003-03-18 2007-10-23 Loma Linda University Medical Center Method and apparatus for detecting embedded rebar within an interaction region of a structure irradiated with laser light
AU2004259705B2 (en) * 2003-07-15 2009-04-23 University Of Maryland, Baltimore Agonist polypeptide of receptor for zot and zonulin
WO2006088491A2 (en) * 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
RU2377019C2 (ru) * 2004-08-03 2009-12-27 Вайтал Хэлф Сайнсис Пти Лтд Транспортирующий наполнитель для энтерального применения
AR053661A1 (es) * 2005-01-14 2007-05-16 Univ Maryland Peptido para entregar vacunas via mucosas
TW200716159A (en) * 2005-06-09 2007-05-01 Univ Maryland Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells
MX2007015949A (es) 2005-06-17 2008-03-07 Vital Health Sciences Pty Ltd Un vehiculo que comprende uno o mas derivados de fosfato de di- y/o mono-(agentes de transferencia de electrones) o complejos de los mismos.
CA2638914C (en) 2006-02-09 2014-04-08 Alba Therapeutics Corporation Formulations for a tight junction effector
US8728491B2 (en) * 2007-05-07 2014-05-20 Alba Therapeutics Corporation Transcutaneous delivery of therapeutic agents
US8198233B2 (en) 2007-07-26 2012-06-12 Alba Therapeutics Corporation Synthetic peptides that enhance tight junction permeability
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
EP2062909A1 (en) 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
AU2011213557B2 (en) 2010-02-05 2015-05-07 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
RU2553350C2 (ru) 2010-03-30 2015-06-10 Фосфейдженикс Лимитед Трансдермальные пластыри
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
KR102061486B1 (ko) 2012-03-19 2020-01-03 시다라 세라퓨틱스, 인코포레이티드 에키노칸딘 계열의 화합물에 대한 투여 용법
CN103923216B (zh) * 2014-04-22 2016-04-27 吉林大学 多功能模块融合蛋白及其在提高蛋白质类药物口服生物利用度中的应用
EP3383371B1 (en) 2015-12-09 2024-05-01 Avecho Biotechnology Limited Pharmaceutical formulation
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法
EP3579863A4 (en) 2017-02-10 2020-11-11 9 Meters Biopharma, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ENVIRONMENTAL ENTEROPATHY

Also Published As

Publication number Publication date
JPH11505844A (ja) 1999-05-25
AU702385B2 (en) 1999-02-18
CA2222018A1 (en) 1996-11-28
US5665389A (en) 1997-09-09
ATE235893T1 (de) 2003-04-15
EP0828481A1 (en) 1998-03-18
EP0828481B1 (en) 2003-04-02
JP2003155253A (ja) 2003-05-27
DE69627147D1 (de) 2003-05-08
EP0828481A4 (en) 1999-06-09
JP3846901B2 (ja) 2006-11-15
AU5792996A (en) 1996-12-11
DE69627147T2 (de) 2003-12-11
WO1996037196A1 (en) 1996-11-28

Similar Documents

Publication Publication Date Title
ES2194989T3 (es) Composicion adminstrada por via oral, que comprende una toxina de zonula occludens y un agente que tiene una actividad biologica, y su utilizacion.
EP1028715A4 (en) FORMULATION FOR NASAL SUPPORT AND METHOD OF USE THEREOF
MY114889A (en) 1-phenyl-3-dimethylamino-propane derivatives having pharmacological activity
NZ333380A (en) 6-O-methylerythromycin A crystal form I (clarithromycin) and preparation thereof
GT199800126A (es) Terapia de combinacion.
BR9609176A (pt) Composi-{es de agente biolÄgico
UA43348C2 (uk) Водна фармацевтична композиція, що включає фактор росту нерва (варіанти) та ліофілізований фармацевтичний склад
NO20002788D0 (no) Nye forbindelser
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
DK0994710T3 (da) Farmaceutiske præparater til oral indgivelse omfattende en benzhydrylpiperazin og en cyclodextrin
DE60019334D1 (de) Antivirale arznei
DZ2509A1 (fr) Analogues peptidiques de la lh-rh leur utilisationet les compositions pharmaceutiques les contenant.
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
ES2195040T3 (es) Conjugado que incluye un principio activo, un polipeptido y varios polieteres y su uso como medicamento.
MA26899A1 (fr) PREPARATIONS CONTENANT UN MEDICAMENT GLUCOCORTICOiDE POUR LE TRAITEMENT DES MALADIES BRONCHOPULMONAIRES.
NO980296L (no) Forbedrede terapeutiske midler
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
DE69804766D1 (de) Isoflavonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
MA26745A1 (fr) Diphosphate d'un derive de 9-deoxo-9a-aza-9a-homoerythromycine substituee en 4", son procede de preparation et composition pharmaceutique le contenant
AU2002211577A1 (en) Protecting therapeutic compositions from host-mediated inactivation
FR2751967B1 (fr) Agents antipaludeens et antibabesioses et compositions pharmaceutiques les contenant
ATE106883T1 (de) Azelastin-embonat, verfahren zu seiner herstellung und pharmazeutische zubereitungen, die als wirkstoff azelastin-embonat enthalten.
MX9803694A (es) Derivados de 3-desoxi-3-desclandinosa de eritromicinas a y b.